Since dyslipidemia is one of the most critical risk factors for CAD and accounts for at least 50% of population-attributable risk [34], it is tempting to speculate that the increased EOCAD risk associated with CD36 variants [32, 33] may stem from atherogenic dyslipidemia. This evidence concerns the gene CD36 and metabolic syndrome.